Abstracts tagged "interstitial lung disease and outcome measures"

Abstract Number: 727 • 2014 ACR/ARHP Annual Meeting
International Classification of Functioning, Disability, and Health (ICF) Core Sets for Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) and Idiopathic Pulmonary Fibrosis (IPF) – a Necessary Map to Health Care Provision in the Era of ICD-11
Reuben Escorpizo^1,2, Kevin J. Keen³, Kim Fligelstone⁴, Matthew R. Lammi⁵, Daphne LeSage⁶, Anne-Marie Russell⁷, Surinder Birring⁸, Catherine Sarver⁹, Janos Varga¹⁰, Oliver Distler¹¹ and Lesley Ann Saketkoo¹², ¹ICF Research Branch in cooperation with the WHO Collaborating Centre for the Family of International Classifications in Germany (DIMDI), Nottwil, Switzerland, ²Department of Physical Therapy, 2Louisiana State University Health Sciences Center, New Orleans, LA, ³University of Northern British Columbia, Health Research Institute, Prince George, BC, Canada, ⁴Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁵Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ⁶Center for CCH at State of Louisiana, New Orleans, LA, ⁷National Heart Lung Institute, Royal Brompton Hospital,, London, United Kingdom, ⁸King's College Hospital NHS Foundation Trust, London, United Kingdom, ⁹Johns Hopkins, Baltimore, MD, ¹⁰National Koranyi Institute for TB and Pulmonology, Budapest, Hungary, ¹¹Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹²Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: A recent consensus project (Saketkoo et al, Thorax 2014) recommended a minimum core set of outcome measures for use in future clinical trials of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].